The London Cord Blood Bank: analysis of banking and transplantation outcome.
Cord blood units (n = 5500) stored at the London Cord Blood Bank, including 59 units transplanted into a high risk and heterogeneous group of patients, were analysed. Transplant outcome data was available for 44 patients with a median clinical follow-up of 14 months (range 3-44 months). Over 40% of the collected units were of ethnic minority origin with a median volume of 79 ml (range 40-240 ml) and a median total nucleated cell (TNC) count of 11.9 x 10(9)/l (range 10.0-24.8 x 10(9)/l). The average patient's weight was 28 kg (range 5-80 kg) and the median age was 8 years (range 0.7-40 years). The median number of nucleated cells infused was 4 x 10(7)/kg (range 1.10-16 x 10(7)/kg). Neutrophil engraftment of 0.5 x 10(9)/l was observed in 33 (74+/-%) patients with an average time of 28 days (range 11-60). The Kaplan-Meier estimate of acute graft-versus-host disease (grade II >) at day 100 was 37 +/- 7% and in 27 (62%) patients, it was grade I or absent. The overall survival and disease-free survival at 2 years was 49 +/- 8% and 41 +/- 8%, respectively. Two years after transplantation the survival rate was 69% and 54% for patients receiving a 6/6 or 5/6 HLA matched units, respectively. Infection was the main cause of transplanted related mortality in these patients.
Davey
Sue
S
The London Cord Blood Bank, National Blood Service, Colindale Centre, London, UK.
Armitage
Sue
S
Rocha
Vanderson
V
Garnier
Federico
F
Brown
Juliette
J
Brown
Colin J
CJ
Warwick
Ruth
R
Fehily
Deidre
D
Watt
Suzanne
S
Gluckman
Eliane
E
Vora
Ajay
A
Contreras
Marcela
M
Navarrete
Cristina V
CV
D000293:Adolescent; D000328:Adult; D001771:Blood Banks / Q000458:organization & administration; D001782:Blood Donors; D001793:Blood Preservation / Q000379:methods; D002648:Child; D002675:Child, Preschool; D015925:Cryopreservation; D005006:Ethnicity; D005260:Female; D005312:Fetal Blood / Q000637:transplantation*; D005500:Follow-Up Studies; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000628:therapy*; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D007223:Infant; D008131:London; D008297:Male; D016896:Treatment Outcome; D000094902:Blood Banking / Q000379:methods*